CNBC's Jim Cramer on Friday highlighted the most market-moving events of next week, including earnings reports from Disney, Palantir and Uber. He also remarked on the turbulent nature of the market as ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

First, he landed his role in "Modern Family," a critically acclaimed ABC sitcom that went on for 11 seasons and catapulted ...